Notably, after surgery and chemotherapy in patients (PD-L1 ≥ 1%) with stage II-IIIA NSCLC, atezolizumab was the only effective adjuvant immunotherapy agent, reducing the risk of disease recurrence or death by 34% compared with best supportive therapy.[41] In the field of stage III unresectable NSCLC, the results of the PACIFIC study[42] showed that consolidation therapy with durvalumab significantly extended survival in patients with no disease progression following concurrent chemoradiotherapy. Here, CD274 is linked to non-small cell lung carcinoma.